MASSDEVICE ON CALL — When Medtronic (NYSE:MDT) in 2007 recalled its Sprint Fidelis defibrillator leads, what was designed as a comparative clinical study turned into a registry of already-treated patients, many of which were children.
The Sprint Fidelis leads were favored for pediatric uses because they were thinner, but a new study suggests that they devices, which were recalled after they were found to be prone to fracture, may fail more often in children than they do in adults.
In a prospective analysis of the Pediatric Lead Extractability & Survival Evaluation registry, researchers found that 1 in 3 Fidelis leads failed, representing 71% of all failures observed in the study, heartwire reported. That compared with a 14% rate of lead failure for the total study population.
The analysis included 878 pediatric patients who from 2005 to 2010 received 965 total leads, 300 of which were the Sprint Fidelis, according to the report.
"Thousands" of medtech layoffs in 2013
Strong earnings and optimistic outlooks aren’t stopping medical device makers from paring their workforces this year, with "thousands" of layoffs so far from companies such as Medtronic (NYSE:MDT), Boston Scientific (NYSE:BSX) and Abbott (NYSE:ABT), according to a Fierce Medical report.
Pelosi on healthcare reform and immigration reform
House Minority Leader Nancy Pelosi (D-Calif.) told reporters last week that the Democratic position on President Barack Obama’s healthcare reform doesn’t include subsidies for illegal immigrants who gain citizenship through immigration reform.
Promising stroke treatment with regenerative medicine
Henry Ford Researchers reported "substantial evidence" that they may be able to help stroke victims recover from disability via regenerative medicine to restore damaged nerves in the spinal cord.